Physician profile
William E Damsky
NPI 1871938381
$22,927.39
in general payments reported to CMS, 2019-2025
12 companies · $48.26 in 2025
The $48.26 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,101 · 2022: $2,817 · 2023: $4,532 · 2024: $9,429 · 2025: $48.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $1,150 · Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,204.83 |
| Travel and Lodging | $1,150.00 |
| Food and Beverage | $654.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $9,361.36 | 2023-2024 | Opzelura |
| Pfizer INC. | $6,164.31 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $2,933.83 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,489.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $1,071.00 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $393.33 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $158.70 | 2023-2025 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $150.68 | 2021-2023 | Dupixent |
| Lilly USA, LLC | $83.17 | 2022 | |
| Genzyme Corporation | $65.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.67 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Damsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.